The Prolyl Hydroxylase Inhibitor BIQ/FG-2216 Stabilises HIF-1 alpha and Upregulates VEGF in vitro: A Potential Strategy For Difficult CTO Lesions in Patients.

Eitemau Tebyg

• 74 Pro-Angiogenic Effects of the Prolyl-hydroxylase Inhibitor FG-2216/BIQ: Therapeutic Angiogenesis for the Treatment of Chronic Total Occlusions.
  gan: Barnett, G, et al.
  Cyhoeddwyd: (2014)
• Pro-angiogenic effects of proly-hydroxylase inhibitor FG-2216 and potential for use in a novel strategy of therapeutic angiogenesis for difficult cases of coronary total occlusion
  gan: Barnett, G, et al.
  Cyhoeddwyd: (2014)
• Enhanced Endothelial Tubule Formation in Response to Proly-Hydroxylase Inhibitor FG-2216: A Step Towards Therapeutic Angiogenesis in Chronic Total Occlusions
  gan: Barnett, G, et al.
  Cyhoeddwyd: (2012)
• Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents.
  gan: Flashman, E, et al.
  Cyhoeddwyd: (2010)
• Regulation of HIF: prolyl hydroxylases.
  gan: Stolze, I, et al.
  Cyhoeddwyd: (2006)